Ephrin-Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies
- PMID: 37103689
- PMCID: PMC10409970
- DOI: 10.1007/s12079-023-00750-1
Ephrin-Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies
Abstract
Hepatic fibrosis is the common pathological change that occurs due to increased synthesis and accumulation of extracellular matrix components. Chronic insult from hepatotoxicants leads to liver cirrhosis, which if not reversed timely using appropriate therapeutics, liver transplantation remains the only effective therapy. Often the disease further progresses into hepatic carcinoma. Although there is an increased advancement in understanding the pathological phenotypes of the disease, additional knowledge of the novel molecular signaling mechanisms involved in the disease progression would enable the development of efficacious therapeutics. Ephrin-Eph molecules belong to the largest family of receptor tyrosine kinases (RTKs) which are identified to play a crucial role in cellular migratory functions, during morphological and developmental stages. Additionally, they contribute to the growth of a multicellular organism as well as in pathological conditions like cancer, and diabetes. A wide spectrum of mechanistic studies has been performed on ephrin-Eph RTKs in various hepatic tissues under both normal and diseased conditions revealing their diverse roles in hepatic pathology. This systematic review summarizes the liver-specific ephrin-Eph RTK signaling mechanisms and recognizes them as druggable targets for mitigating hepatic pathology.
Keywords: Cholangiocarcinoma; Eph RTKs; Ephrins; Hepatic fibrosis; Hepatocellular carcinoma; NAFLD.
© 2023. The International CCN Society.
Conflict of interest statement
The authors declare that they have no conflict of interest
Figures

Similar articles
-
The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.Curr Med Chem. 2023;30(20):2340-2353. doi: 10.2174/0929867329666220820125638. Curr Med Chem. 2023. PMID: 35996244 Review.
-
Recent advances of the Ephrin and Eph family in cardiovascular development and pathologies.iScience. 2024 Jul 19;27(8):110556. doi: 10.1016/j.isci.2024.110556. eCollection 2024 Aug 16. iScience. 2024. PMID: 39188984 Free PMC article. Review.
-
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?Int J Mol Sci. 2022 Dec 21;24(1):93. doi: 10.3390/ijms24010093. Int J Mol Sci. 2022. PMID: 36613532 Free PMC article. Review.
-
Eph receptor tyrosine kinases in cancer stem cells.Cytokine Growth Factor Rev. 2015 Feb;26(1):1-6. doi: 10.1016/j.cytogfr.2014.05.001. Epub 2014 May 17. Cytokine Growth Factor Rev. 2015. PMID: 24933439 Free PMC article. Review.
-
The first identification of complete Eph-ephrin signalling in ctenophores and sponges reveals a role for neofunctionalization in the emergence of signalling domains.BMC Evol Biol. 2019 Apr 25;19(1):96. doi: 10.1186/s12862-019-1418-z. BMC Evol Biol. 2019. PMID: 31023220 Free PMC article.
Cited by
-
Investigating the Antifibrotic Effects of β-Citronellol on a TGF-β1-Stimulated LX-2 Hepatic Stellate Cell Model.Biomolecules. 2024 Jul 5;14(7):800. doi: 10.3390/biom14070800. Biomolecules. 2024. PMID: 39062514 Free PMC article.
-
Various Cellular Components and Its Signaling Cascades Through the Involvement of Signaling Messengers in Keratinocyte Differentiation.Antioxidants (Basel). 2025 Apr 1;14(4):426. doi: 10.3390/antiox14040426. Antioxidants (Basel). 2025. PMID: 40298779 Free PMC article. Review.
References
-
- Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of the diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011;9:283–293. doi: 10.1038/labinvest.2010.166. - DOI - PubMed
-
- Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y. Eph-B2/Ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2013;18:91–105. doi: 10.1158/1078-0432.CCR-11-0111. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous